ExpreS2ion Announces Bavarian Nordic Enters Agreement with AdaptVac to Advance the COVID-19 Vaccine Program
Hørsholm, Denmark, May 06, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that its joint venture AdaptVac has entered into an exclusive head of terms agreement with Bavarian Nordic, a global leader in the development, manufacture and commercialization of life-saving vaccines, to license the COVID-19 vaccine. The parties seek to enter into the final license agreement within the next two months. Upon execution of a final license agreement, Bavarian Nordic will pay AdaptVac an initial upfront payment in addition to future development and sales milestones and royalties.